Fw: NATAP: AASLD Reports

[Guest guest]

_______________________________________________

NATAP AASLD Reports posted so far on the NATAP website

Of note there are reports below on several new HCV protease inhibitors: Merck's MK-7009, its their first presentation at a meeting TMC435 from Tibotec; Vertex's telaprevir, below is their press release but my full data reports were emailed yesterday so they should be posted on website later today; data from the HCV protease inhibitor boceprevir from Schering Plough is reported below. The BMS NS5A inhibitor, BMS-790052 received the most attention althoug the study presented was only of single doses, one dose produced a -3.6 log viral load reduction within 48 hours and patients remained undetectable for 144 hours.

59th Annual Meeting of the American Association

for the Study of Liver Diseases

(AASLD)

Oct 31-Nov 1 2008

San Francisco, CA

Safety and antiviral activity of TMC435350 in treatment-naive genotype 1 HCV-infected patients - (11/04/08)

Safety, Tolerability and Antiviral Activity of MK-7009, a Novel Inhibitor of the Hepatitis C Virus NS3/4A Protease, in Patients with Chronic HCV Genotype 1 Infection - (11/04/08)

GlobeImmune Hepatitis C Therapeutic Vaccine, GI-5005, Doubles Viral Clearance And Increases RVR Rates In Phase 2 Clinical Trial - (11/04/08)

Boceprevir Plus Peginterferon alfa-2b/Ribavirin for Treatment of Genotype 1 Chronic Hepatitis C in Previously Untreated Patients: Interim Results from the HCV SPRINT-1 Study - (11/04/08)

BMS-790052 is a First-in-class Potent Hepatitis C Virus (HCV) NS5A Inhibitor for Patients with Chronic HCV Infection: Results from a Proof-of-concept Study - (11/04/08)

An On-going Outbreak of Acute HCV in HIV-infected Men in New York City: Rates of Spontaneous Clearance, Treatment Responses, and Liver Fibrosis - (11/3/08)

New Clinical Data Support Broad Profile for Telaprevir in Patients with Genotype 1 Hepatitis C Virus (HCV) Infection - (11/3/08)

Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients - (11/3/08)

TIBOTEC PRESENTS INTERIM FINDINGS FOR TMC435, AN INVESTIGATIONAL GENOTYPE 1 HEPATITIS C TREATMENT, AT THE AASLD LIVER MEETING 2008 - (11/3/08)

GILEAD ANNOUNCES TWO-YEAR DATA FROM PIVOTAL PHASE III STUDIES EVALUATING VIREAD FOR CHRONIC HEPATITIS B - (11/3/08)

______________________________________________________________________________________________